Google’s Calico focuses on neurodegenerative disorders R&D

US-based UT Southwestern Medical Center, 2M Companies, and Calico announced a new collaboration to advance research and drug development for neurodegenerative disorders caused by the aging and death of nerve cells


Mr Hal V Barron, president, R&D, Calico

Last week, UT Southwestern researchers published a new paper about the molecular target of P7C3 compounds, a class that has been shown to help in various animal models of neurodegeneration.

UT Southwestern previously licensed the P7C3 compounds to Dallas-based 2M Companies. 2M and Calico have now entered into a new license agreement under which Calico will take responsibility for developing and commercializing the compounds resulting from the research program.

Under the agreement, Calico will fund research laboratories in the Dallas area and elsewhere to support the program.

Mr Hal V Barron, president, R&D, Calico, said, "This is an important collaboration for Calico. We look forward to working with the world-leading scientists who discovered the P7C3 class of molecules to learn whether the remarkable biological effects can be translated to the treatment of human disease."

In 2010, UT Southwestern entered a licensing agreement with 2M Companies for the P7C3 program. Today's agreement between 2M and Calico is an important further step in the process to commercialize these compounds.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email